Can‑Fite BioPharma Ltd. (CANF) received an allowance from the Israeli Patent Office for its application No. 284463, which protects the use of the A3 adenosine receptor agonist Namodenoson for inducing fat loss and treating obesity and related metabolic disorders. The allowance expands the company’s intellectual‑property protection for Namodenoson’s anti‑obesity activity and complements similar approvals in the United States, Canada and Australia.
The patent covers the broader class of A3 adenosine receptor agonists, including Namodenoson, and secures rights to the drug’s unique mechanism of action in obesity. By extending its IP estate in Israel, Can‑Fite strengthens its competitive moat against other oral small‑molecule candidates and positions itself to pursue licensing or partnership opportunities in a market projected to reach $60.5 billion by 2030.
Can‑Fite continues to advance Namodenoson across multiple indications. The company is conducting a Phase III hepatocellular carcinoma trial and a Phase IIb non‑alcoholic steatohepatitis study, while also exploring advanced liver cancer, MASH and pancreatic cancer indications. In addition, Can‑Fite’s pipeline includes Piclidenoson (Phase III for psoriasis) and CF602 (for erectile dysfunction).
"With the allowance of this patent in Israel, we continue to build and strengthen our intellectual property portfolio around Namodenoson's anti‑obesity activity," said Dr. Pnina Fishman, Chairperson and Chief Scientific Officer of Can‑Fite. The expanded patent estate, combined with Namodenoson’s established safety profile and ongoing clinical data, enhances the company’s attractiveness to potential partners and investors looking to capitalize on the growing obesity therapeutics market.
The allowance reinforces Can‑Fite’s strategy to develop a broad portfolio of indications for Namodenoson, positioning the company to capture a share of the expanding obesity market while maintaining a defensible IP position that supports future commercialization and collaboration opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.